Drug Trial Radar · NCT05307874
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
56
Actual
Start
May 4, 2022
Primary completion
Oct 9, 2025
Study completion Oct 9, 2025
Sponsor
- Lead sponsor
- ImCheck Therapeutics, an Ipsen companyIndustry
- Sponsor type
- Industry
- First posted
- Apr 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/IIa, two-part, open-label study to characterize the safety, tolerability, pharmacodynamics, and antitumor activity of ICT01 in combination with LDSC IL-2 in patients with advanced-stage solid tumors. Part 1 will be a dose escalation of IV ICT01 administered on the first day of every 21-day cycle (CnD1) to patients with advanced-stage solid tumors in combination with LDSC IL-2 (Proleukin®) administered daily on days 1-5 of cycles 1-3 (C1-3D1-5). Objectives of part 1 are to characterize the safety of the combination regimen and determine the RP2D for Part 2. Part 2 will comprise a maximum of 2 indications and 2 combination dosing regimens of ICT01 +LDSC IL-2, which will be supported by statistical power calculations once the indications are selected. The final regimen will be ICT01 + LDSC IL-2 + Pembrolizumab on a Q3W cycle. The primary objective of Part 2 is to demonstrate the efficacy of the combination regimen based on RECIST1.1 in one or more solid tumor indications.
Conditions
- Solid Tumor, Adult
Interventions
ICT01Drug
anti-BTN3A mAb IV Q3W
Proleukin Injectable ProductDrug
1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles
Pembrolizumab injectionDrug
200mg administered following ICT01 + LDSC IL-2 over 30 min Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-Emergent Adverse EventsTime frame: 1 year
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Institute Gustave Roussy
Paris, France
IUCT Oncopole Claudius Regaud
Toulouse, France
University Carl Gustav Carus
Dresden, Germany
Universitätsklinikum Wuerzburg
Würzburg, Germany
The Institute of Cancer Research
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.